Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vincerx Pharma, Inc.LSAC · Entity 84409 | Director · Chief Operating Officer · 10% owner | March 05, 2020 | March 09, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vincerx Pharma, Inc.
Report date March 05, 2020 · Filed March 09, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy way of LifeSci Investments, LLC | 1,701,000 |
Reported balance
Holding disclosure · report date 2020-03-05 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,701,000 F1: Mr. Rice is a managing member of LifeSci Investments, LLC. He disclaims any pecuniary interest in the securities except to the extent of his ownership interest in LifeSci Investments, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Rice is a managing member of LifeSci Investments, LLC. He disclaims any pecuniary interest in the securities except to the extent of his ownership interest in LifeSci Investments, LLC.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date October 30, 2023 · Filed November 01, 2023
Section 16 reporting ended · disclosed 2023-11-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 347,085 |
Reported balance
After 2023-10-30 transaction · row 1
1 source rowRow 1 · 2023-10-30 · Sale · Disposed 72,603 · Balance 347,085 F1: The sale reported herein was made pursuant to Rule 10b5-1 (c) trading plans adopted by the reporting person effective as of 03-25-2020, 02-08-21, 02-24-2022, and 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported herein was made pursuant to Rule 10b5-1 (c) trading plans adopted by the reporting person effective as of 03-25-2020, 02-08-21, 02-24-2022, and 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 30, 2023 Filed Nov 1, 2023 21:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 72,603 | $9.13 | $662,865.39 |
DisclosureSEC source: 0001628280-23-036053 · wk-form4_1698874195.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Former CEO and Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 347,085 F1 · kind: The sale reported herein was made pursuant to Rule 10b5-1 (c) trading plans adopted by the reporting person effective as of 03-25-2020, 02-08-21, 02-24-2022, and 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| October 22, 2023 Filed Oct 24, 2023 23:45 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 771 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-035027 · wk-form4_1698191120.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Former CEO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 419,688 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| October 08, 2023 Filed Oct 10, 2023 21:25 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 282 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-034200 · wk-form4_1696973124.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 418,917 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| September 28, 2023 Filed Oct 2, 2023 21:07 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 831 | $14.16 | $11,766.96 |
DisclosureSEC source: 0001628280-23-033507 · wk-form4_1696280818.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 418,635 F2 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-25-2020 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| September 24, 2023 Filed Oct 2, 2023 21:07 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 290 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-033507 · wk-form4_1696280818.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 419,466 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| September 10, 2023 Filed Sep 12, 2023 20:47 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 1,022 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-032088 · wk-form4_1694551634.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 419,176 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| August 27, 2023 Filed Aug 30, 2023 21:38 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 1,248 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-031004 · wk-form4_1693431476.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 418,154 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| August 25, 2023 Filed Aug 29, 2023 21:53 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,729 | $10.99 | $19,001.71 |
DisclosureSEC source: 0001628280-23-030915 · wk-form4_1693345983.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 416,906 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 20:49 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 277 | $12.38 | $3,429.26 |
DisclosureSEC source: 0001628280-23-029688 · wk-form4_1692218968.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 418,635 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 20:40 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 877 | $22.91 | $20,092.07 |
DisclosureSEC source: 0001628280-23-023916 · wk-form4_1688071205.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 418,912 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-25-2020 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| May 31, 2023 Filed Jun 3, 2023 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,679 | $23.21 | $38,969.59 |
DisclosureSEC source: 0001437749-23-016542 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 419,789 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| May 17, 2023 Filed May 18, 2023 01:52 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 33,333 | $21.04 | $701,326.32 |
DisclosureSEC source: 0001437749-23-015004 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 421,468 F2 · kind: The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 09-14-2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.18, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 15, 2023 Filed May 18, 2023 01:52 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 190 | $18.71 | $3,554.90 |
DisclosureSEC source: 0001437749-23-015004 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 454,801 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock granted on February 8, 2021. Read SEC document |
| April 06, 2023 Filed Apr 10, 2023 23:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 3,214 | $20.03 | $64,376.42 |
DisclosureSEC source: 0001437749-23-009876 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 447,480 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| April 06, 2023 Filed May 17, 2023 01:48 UTC Amendment | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 3,214 | $20.03 | $64,376.42 |
DisclosureSEC source: 0001437749-23-014861 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 454,991 F2 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. F3 · balance_after: This reflects the total amount beneficially owned by the reporting person as of April 10, 2023. Subsequent Form 4's filed by the reporting person after April 10, 2023 do not currently reflect the vesting of the 7,511 shares. Read SEC document |
| March 31, 2023 Filed May 17, 2023 01:48 UTC Amendment | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionRestricted Stock Award · Derivative | 7,511 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-014861 · rdgdoc.xml · derivative · entry 3 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,511 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F1 · derivative.expiration_date: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| March 31, 2023 Filed May 17, 2023 01:48 UTC Amendment | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 7,511 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-014861 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 458,205 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F1 · price: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 23:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 936 | $20.62 | $19,300.32 |
DisclosureSEC source: 0001437749-23-008894 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,694 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 07, 2023 Filed Mar 10, 2023 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 549 | $22.95 | $12,599.55 |
DisclosureSEC source: 0001437749-23-006041 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 451,630 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 4,290 | $22.75 | $97,597.50 |
DisclosureSEC source: 0001437749-23-005441 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,179 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 09, 2023 Filed Feb 14, 2023 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 144 | $24.60 | $3,542.40 |
DisclosureSEC source: 0001437749-23-003205 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,469 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| January 03, 2023 Filed Jan 11, 2023 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantRestricted Stock Award · Derivative | 99,038 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-000814 · rdgdoc.xml · derivative · entry 2 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,038 Underlying: Common Stock · 99,038 shares Expires not disclosed F2 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F2 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F2 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. Read SEC document |
| January 03, 2023 Filed Jan 11, 2023 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 99,038 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-000814 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,613 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2023 compensation. Read SEC document |
| December 28, 2022 Filed Dec 31, 2022 00:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 898 | $16.90 | $15,176.20 |
DisclosureSEC source: 0001437749-22-029957 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357,575 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| November 29, 2022 Filed Dec 1, 2022 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 931 | $19.93 | $18,554.83 |
DisclosureSEC source: 0001437749-22-028234 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 358,473 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| November 23, 2022 Filed Nov 29, 2022 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GiftCommon Stock | 2,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-028121 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,404 F1 · kind: This transaction represents a charitable donation to a charity. No value was received for the gifted shares. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 01:08 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 164 | $23.16 | $3,798.24 |
DisclosureSEC source: 0001437749-22-027400 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,154 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| September 29, 2022 Filed Oct 1, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 830 | $23.02 | $19,106.60 |
DisclosureSEC source: 0001437749-22-023339 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,318 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| August 31, 2022 Filed Sep 2, 2022 00:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 906 | $23.44 | $21,236.64 |
DisclosureSEC source: 0001437749-22-021729 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,148 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| August 14, 2022 Filed Aug 17, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 504 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-020750 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,054 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 171 | $23.17 | $3,962.07 |
DisclosureSEC source: 0001437749-22-020214 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,550 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| July 29, 2022 Filed Aug 3, 2022 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 643 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-018512 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,721 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| July 17, 2022 Filed Jul 20, 2022 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 779 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-017384 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,078 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| July 03, 2022 Filed Jul 7, 2022 00:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 847 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-016770 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,299 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| June 28, 2022 Filed Jul 1, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 889 | $14.86 | $13,210.54 |
DisclosureSEC source: 0001437749-22-016323 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,452 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| June 19, 2022 Filed Jun 22, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 899 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-015532 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,341 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| June 05, 2022 Filed Jun 8, 2022 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 901 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-014539 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,442 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant. Read SEC document |
| May 27, 2022 Filed Jun 2, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 749 | $14.53 | $10,882.97 |
DisclosureSEC source: 0001437749-22-014058 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,541 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| May 22, 2022 Filed May 25, 2022 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 964 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-013463 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,290 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the at the last closing price as of the date of grant. Read SEC document |
| May 13, 2022 Filed May 18, 2022 00:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 165 | $12.32 | $2,032.80 |
DisclosureSEC source: 0001437749-22-012850 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,326 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 00:17 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 24,400 | $17.59 | $429,196.00 |
DisclosureSEC source: 0001437749-22-009264 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,491 F1 · date: The sales reported herein were made by a broker to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. The sales were made by the broker on April 13, 2022, April 14, 2022 and April 18, 2022. The high sales price during the period was $19.22, the low sales price during the period was $16.33 and the weighted average sales price was $17.59. F1 · kind: The sales reported herein were made by a broker to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. The sales were made by the broker on April 13, 2022, April 14, 2022 and April 18, 2022. The high sales price during the period was $19.22, the low sales price during the period was $16.33 and the weighted average sales price was $17.59. F1 · price: The sales reported herein were made by a broker to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. The sales were made by the broker on April 13, 2022, April 14, 2022 and April 18, 2022. The high sales price during the period was $19.22, the low sales price during the period was $16.33 and the weighted average sales price was $17.59. Read SEC document |
| April 13, 2022 Filed Apr 14, 2022 01:19 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0001437749-22-008915 · rdgdoc.xml · derivative · entry 8 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 10,000 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: On March 15, 2016, the reporting person was granted an option to purchase 100,000 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| April 13, 2022 Filed Apr 14, 2022 01:19 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $19.06 | $190,600.00 |
DisclosureSEC source: 0001437749-22-008915 · rdgdoc.xml · nonDerivative · entry 5 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,891 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of May 21, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.61 to $19.28, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 13, 2022 Filed Apr 14, 2022 01:19 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.90 | $19,000.00 |
DisclosureSEC source: 0001437749-22-008915 · rdgdoc.xml · nonDerivative · entry 4 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,891 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2022 Filed Apr 14, 2022 01:19 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionRestricted Stock Award · Derivative | 57,736 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-008915 · rdgdoc.xml · derivative · entry 7 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 57,736 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The restricted stock was granted pursuant to BioLife Solutions 2013 Performance Incentive Plan (as amended). In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F3 · derivative.expiration_date: The restricted stock was granted pursuant to BioLife Solutions 2013 Performance Incentive Plan (as amended). In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| April 12, 2022 Filed Apr 14, 2022 01:19 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 57,736 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-008915 · rdgdoc.xml · nonDerivative · entry 3 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,891 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The restricted stock was granted pursuant to BioLife Solutions 2013 Performance Incentive Plan (as amended). In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F3 · price: The restricted stock was granted pursuant to BioLife Solutions 2013 Performance Incentive Plan (as amended). In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| April 11, 2022 Filed Apr 14, 2022 01:19 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 10,000 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0001437749-22-008915 · rdgdoc.xml · derivative · entry 6 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 10,000 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: On March 15, 2016, the reporting person was granted an option to purchase 100,000 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| April 11, 2022 Filed Apr 14, 2022 01:19 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $19.55 | $195,500.00 |
DisclosureSEC source: 0001437749-22-008915 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,155 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of May 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.13 to $19.98, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 11, 2022 Filed Apr 14, 2022 01:19 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.90 | $19,000.00 |
DisclosureSEC source: 0001437749-22-008915 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 29, 2022 Filed Apr 1, 2022 00:18 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 830 | $22.24 | $18,459.20 |
DisclosureSEC source: 0001437749-22-007914 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,155 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.